In the context of colitis, STAT1 is implicated in mediating the pro-inflammatory effects of GBP5 (44), and the therapeutic efficacy of Tofacitinib in treating ulcerative colitis is associated with the downregulation of STAT1 expression (45). Here, STAT1 is linked to colitis.